戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              NNRTI concentrations were measured by sensitive high-per
2                                              NNRTI regimen choice and preexisting NNRTI-resistant min
3                                              NNRTI resistance was particularly high in children expos
4                                              NNRTIs are noncompetitive inhibitors that bind in a hydr
5                                              NNRTIs are recommended components of highly active antir
6                                              NNRTIs modestly affect liver stage Plasmodium parasites,
7 9%] of 597 patients without TAMs; p<0.0001), NNRTI resistance (107 [93%] vs 462 [77%]; p<0.0001), and
8 ruption, 22/131 (16.8%) patients showed >/=1 NNRTI-RAM, including eight patients with NNRTI-RAMs dete
9 tions, compared to the use of 2 NRTIs plus 1 NNRTI.
10 hiral indolyarylsulfones (IASs) as new HIV-1 NNRTIs.
11 children randomised to WHO-recommended 2NRTI+NNRTI long-term ART, 308/378 (81%) monitored with CD4 co
12 ily in the nonfunctional, solvent-accessible NNRTI binding pocket.
13 MTCT), a substantial proportion will acquire NNRTI-resistant HIV, potentially compromising response t
14 s) were continued for median nine days after NNRTI interruption, did not prevent NNRTI-RAMs, but incr
15                             Four weeks after NNRTI interruption, 19/31 (61.3%) and 34/39 (87.2%) pati
16 d in cellulo antiretroviral activity against NNRTI-resistant strains.
17 istant C181 lineage also resulted in altered NNRTI sensitivity and a net fitness cost.
18 NNRTI strategy"), all individuals who had an NNRTI-resistance mutation identified by ultra-deep seque
19 ch a switch compared with continuation of an NNRTI-containing regimen.
20 50 copies per mL for at least 6 months on an NNRTI plus emtricitabine and tenofovir regimen.
21 apy after first-line virologic failure on an NNRTI regimen.
22 be a suitable alternative for patients on an NNRTI with emtricitabine and tenofovir regimen consideri
23 dues involved in template/primer binding and NNRTI binding.
24 08.2; P<.0001), while protease inhibitor and NNRTI replacement rates were similar.
25  drug resistance, primarily due to M184V and NNRTI mutations, has been identified in 60%-72%, althoug
26 z-containing therapy in both NNRTI-naive and NNRTI-experienced patients and to determine their associ
27 vity against multidrug (IC(50) = 5.9 nM) and NNRTI (IC(50) = 12.9 nM) resistant viruses than parent n
28 DR to PI and NRTI was seen in 1.6%, NRTI and NNRTI in 3.4%, and triple class TDR in 0.9%.
29  mutations; and 30 (66.7%) had both NRTI and NNRTI mutations.
30 ptase (RT) mutation associated with NRTI and NNRTI resistance, respectively.
31 N and RH mutations can exhibit dual NRTI and NNRTI resistance.
32 in drug-resistance patterns in both NRTI and NNRTI were observed by site.
33                                  Both PI and NNRTI use was associated with increases in APRI over tim
34 ed in gag and in gp41-CD in both the PI- and NNRTI-treated groups.
35   Resistance-associated mutations (RAMs) and NNRTI concentrations were studied in plasma from 132 pat
36 mplexes is hindered by a kinetic barrier and NNRTIs mostly interact with free RT.
37  hinge points for this essential motion, and NNRTIs therefore act as "molecular wedges," sterically b
38  reverse transcriptase inhibitors (NRTIs and NNRTIs).
39  reverse transcriptase inhibitors (NRTIs and NNRTIs).
40 ecular mechanisms of resistance to NRTIs and NNRTIs, and their complex relationships, may help in des
41         Additionally, we showed that another NNRTI, nevirapine (NVP), stimulated K101E+G190S virus re
42  rilpivirine, the most recently FDA-approved NNRTI, bear a cyanovinylphenyl (CVP) group.
43 nd have lower cytotoxicity than the approved NNRTI drugs efavirenz and rilpivirine.
44 -Saharan Africa at any prevalence of pre-ART NNRTI resistance.
45 the risk of viral failure at week 48 between NNRTI and bPI (P = .19).
46   At week 48, the overall difference between NNRTI- and PI-based regimens in selection of any major N
47  difference in prevalence of M184V/I between NNRTI and PI (crude unweighted prevalence 3.2% vs 1.4%);
48    To explore potential interactions between NNRTI and INSTI resistance mutations, we investigated th
49 nalysis to evaluate the relationship between NNRTI-resistant minority variants and the likelihood and
50 ltidrug efavirenz-containing therapy in both NNRTI-naive and NNRTI-experienced patients and to determ
51 f sub-Saharan Africa; this rise is driven by NNRTI resistance in studies from east and southern Afric
52 tance to nevirapine or efavirenz imparted by NNRTI mutations.
53 mpound I and efavirenz, the standard of care NNRTI.
54 the observation that mutant viruses carrying NNRTI plus INSTI resistance mutations had reduced amount
55                             We characterized NNRTI and TMP-SMX effects on Plasmodium liver stages in
56 ference in prevalence of K65R when comparing NNRTI (1.3%) with PI (0.67%); absolute weighted differen
57 tion of the NNIBP that may be used to design NNRTIs.
58 TI) and a TMC-derivative (a diarylpyrimidine NNRTI) linked via a poly(ethylene glycol) (PEG) linker.
59 tance is dependent upon the affinity of each NNRTI to the RT and further influenced by the presence o
60 hus, the development of novel more effective NNRTIs as anti-HIV-1 agents with fewer long-term liabili
61 ce, also reduce RNase H cleavage and enhance NNRTI resistance in the context of the patient RT pol do
62 the resumption of DNA synthesis and enhanced NNRTI resistance.
63 etween RT and IN mutations are important for NNRTI and INSTI resistance and viral fitness.
64 DR-associated mutations were more common for NNRTIs (5.4%), followed by nucleoside reverse transcript
65 e patterns on susceptibility was largest for NNRTIs.
66                                         Four NNRTI SDRMs-K101E, K103N, Y181C, and G190A-accounted for
67 guided design to develop two next-generation NNRTI drug candidates, compounds I and II, which are mem
68 o examine the prevalence of 1(st)-generation NNRTI resistance in Europe, the United States (US), and
69 inhibits HIV-1 resistant to first generation NNRTIs.
70 ome a barrier to the use of 1(st)-generation NNRTIs and the increased costs associated with regimen f
71               Resistance to 1(st)-generation NNRTIs is found among treated and untreated HIV-infected
72 n which more than 10% of ART initiators have NNRTI resistance.
73 everse-transcriptase inhibitors (hereafter, "NNRTI strategy"), all individuals who had an NNRTI-resis
74 ariable logistic regression analysis, higher NNRTI minority variant copy numbers, non-white race, and
75 of an RT-DNA-nevirapine complex revealed how NNRTI binding forbids RT from forming a polymerase compe
76 scence anisotropy approaches to discover how NNRTIs modulate the intra-molecular conformational chang
77 e were detected more often at study entry in NNRTI-experienced patients than NNRTI-naive patients by
78 ugh 2013, driven primarily by an increase in NNRTI resistance.
79 TI-resistant variants were more prevalent in NNRTI-experienced patients and were associated with redu
80 tant with NNRTI BP mutants further increases NNRTI resistance from 3- to 30-fold, supporting the role
81 eoside reverse-transcriptase (RT) inhibitor (NNRTI) resistance mutations (from 0.3% to 7.1%), particu
82 eoside reverse transcriptase (RT) inhibitor (NNRTI) that efficiently inhibits HIV-1 resistant to firs
83 nnucleoside reverse transcriptase inhibitor (NNRTI) and a common component of clinically approved ant
84 -nucleoside reverse transcriptase inhibitor (NNRTI) based FDC of rilpivirine plus tenofovir disoproxi
85 -nucleoside reverse transcriptase inhibitor (NNRTI) binding site.
86 -nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (EFV) showed subunit-specific perturbat
87 nnucleoside reverse transcriptase inhibitor (NNRTI) MIV-150 in carrageenan reduced vaginal infection
88 nnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.9%) and protease inhibitor mutations
89 nnucleoside reverse-transcriptase inhibitor (NNRTI) mutations (hazard ratio, 77.5; 95% confidence int
90 -nucleoside reverse transcriptase inhibitor (NNRTI) or 3 NRTIs as long-term ART.
91 -nucleoside reverse transcriptase inhibitor (NNRTI) or who are on a multitablet NNRTI-containing regi
92 nnucleoside reverse-transcriptase inhibitor (NNRTI) regimen in Africa and Asia, comparing the genotyp
93 -nucleoside reverse-transcriptase inhibitor (NNRTI) resistance in people initiating antiretroviral th
94 nnucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations are associated with an incre
95 nnucleoside reverse-transcriptase inhibitor (NNRTI) resistance, and 4.2% had protease inhibitor (PI)
96 nnucleoside reverse transcriptase inhibitor (NNRTI) resistance.
97 -nucleoside reverse transcriptase inhibitor (NNRTI) resistance.
98 -nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TMC278; Tibotec Pharmaceuticals, Co
99 nnucleoside reverse transcriptase inhibitor (NNRTI)- or lopinavir/ritonavir (LPV/r)-based regimen wer
100 nnucleoside reverse-transcriptase inhibitor (NNRTI)-based (hazard ratio, 7.10; 95% confidence interva
101 nnucleoside reverse-transcriptase inhibitor (NNRTI)-based ART.
102 -nucleoside reverse transcriptase inhibitor (NNRTI)-based highly active antiretroviral therapy (HAART
103 -nucleoside reverse-transcriptase inhibitor (NNRTI)-based regimen to one including a protease inhibit
104 nnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens with a backbone of tenofovir/emtri
105 nnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens.
106 nnucleoside reverse-transcriptase inhibitor (NNRTI)-based therapy suggest that 76%-90% of living pati
107 -nucleoside reverse transcriptase inhibitor (NNRTI)-resistant mutants have been shown to emerge after
108 nnucleoside reverse-transcriptase inhibitor (NNRTI)-resistant variants at the initiation of multidrug
109 nnucleoside reverse-transcriptase inhibitor (NNRTI)-resistant variants on the risk of virologic failu
110 -nucleoside reverse transcriptase inhibitor (NNRTI).
111 nnucleoside reverse transcriptase inhibitor (NNRTI; N = 52) or protease inhibitor (PI; N = 42).
112 -nucleoside reverse transcriptase inhibitor (NNRTI; nevirapine or efavirenz) in sub-Saharan Africa.
113 is pocket binds nonnucleoside RT inhibitors (NNRTI); therefore, NNRTI sensitivity was used to probe e
114 oside reverse transcriptase (RT) inhibitors (NNRTI) and integrase (IN) strand transfer inhibitors (IN
115 nucleoside reverse transcriptase inhibitors (NNRTI) 3 and 4 with HIV-1 reverse transcriptase (RT).
116 nucleoside reverse transcriptase inhibitors (NNRTI) efavirenz (EFV) and nevirapine (NVP) in first-lin
117 nucleoside reverse transcriptase inhibitors (NNRTI) in east Africa (36% per year [21 to 52]; p<0.0001
118 nucleoside reverse transcriptase inhibitors (NNRTI), which are similar in structure to earlier descri
119 nucleoside reverse transcriptase inhibitors (NNRTI; Efavirenz, Etravirine, Rilpivirine and Nevirapine
120  (NRTIs) and five non-nucleoside inhibitors (NNRTIs) are approved HIV-1 drugs.
121 elopment of novel non-nucleoside inhibitors (NNRTIs) with activity against variants of HIV reverse tr
122 sms compared to nonnucleoside RT inhibitors (NNRTIs) and nucleoside/nucleotide RT inhibitors (NRTIs).
123                Non-nucleoside RT inhibitors (NNRTIs) are a class of highly specific drugs which bind
124 n of RT and of non-nucleoside RT inhibitors (NNRTIs) by isothermal titration calorimetry (ITC).
125 nucleoside and non-nucleoside RT inhibitors (NNRTIs) by mechanisms that are not well understood.
126 sistance to the nonnucleoside RT inhibitors (NNRTIs) nevirapine and delavirdine.
127 de (NRTIs) and non-nucleoside RT inhibitors (NNRTIs) when combined with certain mutations.
128 s resistant to non-nucleoside RT inhibitors (NNRTIs), suggesting the involvement of binding site(s) o
129 he discovery of nonnucleoside RT inhibitors (NNRTIs).
130 oside reverse transcriptase (RT) inhibitors (NNRTIs) are hindered by their unsatisfactory pharmacokin
131 oside reverse transcriptase (RT) inhibitors (NNRTIs) are important components of multidrug therapy fo
132 oside reverse transcriptase (RT) inhibitors (NNRTIs) are routinely used to treat HIV-1 infection, yet
133 nucleoside reverse transcriptase inhibitors (NNRTIs) and 2 protease inhibitors (PIs).
134 nucleoside reverse transcriptase inhibitors (NNRTIs) are potent and commonly prescribed antiviral age
135 nucleoside reverse transcriptase inhibitors (NNRTIs) are usually part of first-line treatment regimen
136 nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz and nevirapine are commonly used in fi
137 nucleoside reverse transcriptase inhibitors (NNRTIs) has been associated with baseline human immunode
138 nucleoside reverse transcriptase inhibitors (NNRTIs) have been observed among previously untreated in
139 nucleoside reverse transcriptase inhibitors (NNRTIs) have inherent flexibility, helping to maintain a
140 nucleoside reverse transcriptase inhibitors (NNRTIs) in pregnant and breastfeeding women will result
141 nucleoside reverse transcriptase inhibitors (NNRTIs) measured in the population starting ART.
142 nucleoside reverse transcriptase inhibitors (NNRTIs) might compromise HIV control in low-income and m
143 nucleoside reverse transcriptase inhibitors (NNRTIs) play a central role in the treatment of AIDS, bu
144 nucleoside reverse transcriptase inhibitors (NNRTIs) reached 45% (95% CI: 27-64%) in 2015, all based
145 nucleoside reverse transcriptase inhibitors (NNRTIs) that target the viral polymerase have been a key
146 nucleoside reverse-transcriptase inhibitors (NNRTIs) was observed among VCT clients aged 18-21 years.
147 nucleoside reverse transcriptase inhibitors (NNRTIs) with a novel aryl-phospho-indole (APhI) scaffold
148 nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs) among primigravid
149 nucleoside reverse transcriptase inhibitors (NNRTIs), and their biological activity was evaluated.
150 nucleoside reverse transcriptase inhibitors (NNRTIs), nucleotide substrates, Mg ions, temperature, an
151 nucleoside reverse transcriptase inhibitors (NNRTIs).
152 nucleoside reverse transcriptase inhibitors (NNRTIs).
153 nucleoside reverse transcriptase inhibitors [NNRTIs]), integrase strand transfer inhibitors, and viru
154 nucleoside reverse transcriptase inhibitors [NNRTIs], and 60.3% [P = 0.94] in patients receiving NNRT
155 dictive of reduced susceptibility to initial NNRTI-based regimens: 4.5% and 6.5% of patient isolates
156  involving ART-naive participants initiating NNRTI-based regimens were included.
157 up O lineage resulted in a loss of intrinsic NNRTI resistance and was accompanied by fitness loss.
158 resistance mutations, particularly involving NNRTI resistance, were significantly associated with a d
159 ons in both groups, suggesting that isolated NNRTI-associated transmitted drug resistance may not be
160 r individuals to whom variants with isolated NNRTI-associated drug resistance were transmitted are at
161 ce mutations in 33 individuals with isolated NNRTI-associated transmitted drug resistance and 49 matc
162 alogue mutations (T215F, D67N, K70R, K219Q), NNRTIs (L100I, Y181C, K103N, V108I, Y188L), and PIs (V82
163 g the Incoming Nucleotide Binding, Knuckles, NNRTI Adjacent, and 399 sites, located in the polymerase
164              Three of these sites (Knuckles, NNRTI Adjacent, and Incoming Nucleotide Binding) are inh
165  regimen compared with zidovudine/lamivudine/NNRTI, PI resistance at switch (6.69; 2.49-17.98; P < .0
166 al failure of the WHO-recommended first-line NNRTI-based regimen was higher in the presence of K103N.
167 inst RT variants carrying one of three major NNRTI resistance mutations: K103N, Y181C, or G190A.
168                                        Minor NNRTI-resistant variants were more prevalent in NNRTI-ex
169 103N and Y181C) to detect and quantify minor NNRTI-resistant variants.
170 3.0% and 8.8% having resistance to 1 or more NNRTI or nucleoside reverse transcriptase inhibitors, re
171 nhibitor (NNRTI) or who are on a multitablet NNRTI-containing regimen and want a regimen simplificati
172 re 1.3, 1.9, and 2.2 years in the ART-naive, NNRTI, and PI groups, respectively (P = .01).
173 ong potential for further development as new NNRTIs for the potential treatment of HIV infection.
174 ent results highlight the chiral IASs as new NNRTIs with improved resistance profile against the muta
175 ce in untreated patients and impact on newer NNRTIs.
176 nfection similar to EFV, but that the newest NNRTI, etravirine (ETR), did not.
177 ological failure during treatment with a non-NNRTI-containing regimen, we identified minority variant
178 ological failure during treatment with a non-NNRTI-containing regimen.
179   The short and practical synthesis of novel NNRTI relies on two sequential Pd-catalyzed aminations a
180 tor (NRTI) mutations; 33 (73%) had non-NRTI (NNRTI) mutations; and 30 (66.7%) had both NRTI and NNRTI
181 ingly, two subjects had major DRMs to NRTIs, NNRTIs, and 4 mutations in the Gag P2/NC CS.
182 lass TDR was 10.0%, 5.1%, and 1.6% to NRTIs, NNRTIs, and PIs.
183            Triple-class resistance to NRTIs, NNRTIs, and PR inhibitors was observed in 24 (53%) patie
184 nucleotide analog (NRTI) and non-nucleoside (NNRTI) drugs used in treating HIV-1 infections.
185 C was received by 67% of PI users and 69% of NNRTI users.
186 103N, Y181C, and G190A-accounted for >80% of NNRTI-associated TDR in all regions and subtypes.
187                      In SSA and SSEA, 89% of NNRTI SDRMs were associated with high-level resistance t
188                                The degree of NNRTI and NRTI resistance after first-line virologic fai
189 se data are promising for the development of NNRTI-containing gels to prevent rectal HIV transmission
190 RTI resistance and also offset the effect of NNRTI resistance mutations thereby restoring NNRTI bindi
191                  Understanding the effect of NNRTI-resistant mutants on virus replication and reverse
192 reased risk of resistance-related failure of NNRTI/NRTI second-line regimens.
193 e detailed understanding of the mechanism of NNRTI inhibition and the effect of binding upon domain m
194                            A small number of NNRTI-resistance mutations were responsible for most cas
195                                  The odds of NNRTI-associated TDR also increased in Latin America/Car
196              The adjusted odds ratio (OR) of NNRTI-RAM detection was 7.62 (95% confidence interval [C
197                 The long-term persistence of NNRTI and protease inhibitor mutations suggests a risk f
198                         Minor populations of NNRTI-resistant variants that were missed by standard ge
199 RT and further influenced by the presence of NNRTI-binding pocket (BP) mutants.
200 risk of virologic failure in the presence of NNRTI-resistant minority variants.
201 men became cost effective at a prevalence of NNRTI resistance higher than 15%, for cost-effectiveness
202                   The reported prevalence of NNRTI resistance was generally higher in US/Canada than
203 argely on the country-specific prevalence of NNRTI resistance.
204 activity (EC50<1 nM) against a wide range of NNRTI-resistant viruses and a favorable pharmacokinetic
205 an region could face an unidentified rise of NNRTI-resistant HIV.
206 ne use were associated with a higher risk of NNRTI resistance at virologic failure.
207 e from 3- to 30-fold, supporting the role of NNRTI-RT affinity in our NNRTI resistance model.
208 l structure data suggest that the binding of NNRTIs forces RT into a wide-open conformation in which
209                                   Binding of NNRTIs to preformed RT/DNA complexes is hindered by a ki
210 rpretation of the mechanism of inhibition of NNRTIs.
211 fect of the reduction in RNase H cleavage on NNRTI resistance is dependent upon the affinity of each
212  users (8% per 5 years, 95% CI, -3%, 19%) or NNRTI users (3% per 5 years, 95% CI, -7%, 12%).
213 61 individuals with VF on a PI/r (n = 40) or NNRTI (n = 20) containing regimen.
214 d to either lopinavir-ritonavir-based ART or NNRTI-based ART and were followed for 6 months to 2 year
215 nitiated antiretroviral therapy with a PI or NNRTI and a backbone containing either TDF/FTC or ABC/3T
216 sistance to tenofovir, cytosine analogue, or NNRTIs.
217                                For the other NNRTI mutants, reductions in RT content decreased both p
218 mong studied drugs, Efavirenz, but not other NNRTIs, altered claudin-5 expression, increased endothel
219 porting the role of NNRTI-RT affinity in our NNRTI resistance model.
220 these results confirm key predictions of our NNRTI resistance model and provide support for a unifyin
221         NNRTI regimen choice and preexisting NNRTI-resistant minority variants were both associated w
222 ing supports the use of EFV as the preferred NNRTI in first-line treatment regimen for HIV treatment,
223 e were substantial increases in pretreatment NNRTI resistance per year in all regions.
224 nd considered the prevalence of pretreatment NNRTI drug resistance in 2017.
225 her, and with the prevalence of pretreatment NNRTI resistance greater than 10%, a policy to measure v
226         Prevalence estimates of pretreatment NNRTI resistance in 2016 were 11.0% (7.5-15.9) in southe
227      In 2016, the prevalence of pretreatment NNRTI resistance was near WHO's 10% threshold for changi
228 respective of the prevalence of pretreatment NNRTI resistance, because of the increased cost of the p
229 articipants who had low- and high-prevalence NNRTI-resistant variants.
230 ys after NNRTI interruption, did not prevent NNRTI-RAMs, but increased detection of NRTI-RAMs (OR 4.2
231  170 received the study regimen: 86 received NNRTI-based ART, and 84 lopinavir-ritonavir-based ART.
232 lts (55% female) were enrolled: 20 receiving NNRTI-based and 20 receiving LPV/r-based treatment.
233 eligible for ART or were currently receiving NNRTI-based ART were randomly assigned to either lopinav
234 00 (90% CI, .92-1.09) for patients receiving NNRTI- and LPV/r-based treatment, respectively.
235 , and 60.3% [P = 0.94] in patients receiving NNRTIs only).
236 o observed that K103N, a clinically relevant NNRTI resistance mutation, does not prevent binding betw
237                             After restarting NNRTI-based ART (n = 90), virologic suppression rates <4
238 NNRTI resistance mutations thereby restoring NNRTI binding.
239 rm high-affinity dead-end complexes, both RT/NNRTI/DNA complexes being unable to bind the incoming nu
240                              Once formed, RT/NNRTI complexes bind DNA either in a seemingly polymeras
241           HIV-1-specific nonnucleoside RTIs (NNRTIs), protease inhibitors (PIs), and integrase inhibi
242                              Our data showed NNRTI treatment modestly reduced P. yoelii liver stage p
243 (IC50) of EFV than viruses carrying a single NNRTI mutation.
244               We measured the fitness of six NNRTI-resistant mutants, the K103N, V106A, Y181C, G190A,
245 ble for the development of extended-spectrum NNRTIs.
246                                     STRATEGY-NNRTI is a 96 week, international, multicentre, randomis
247  to emerge after interruption of suppressive NNRTI-based antiretroviral therapy (ART) using routine t
248 udy entry in NNRTI-experienced patients than NNRTI-naive patients by both single-genome sequencing (8
249                                We found that NNRTI binding to RT induces opening of the fingers and t
250 e most recent time-based trends suggest that NNRTI-resistance prevalence may be stable or decreasing.
251                   It is widely believed that NNRTIs function as "molecular wedges", disrupting the re
252                                          The NNRTI resistance mutations had no effect on RAL suscepti
253 a9-strand that involve the YMDD loop and the NNRTI binding pocket.
254 e design of more effective inhibitors at the NNRTI site and also drive the identification of novel al
255 and tenofovir (switch group) or continue the NNRTI plus emtricitabine and tenofovir regimen (no-switc
256 ors (IIs) did not affect HK2, except for the NNRTI etravirine (ETV).
257 ase H cleavage and provide more time for the NNRTI to dissociate from the RT, resulting in the resump
258 We demonstrate that changes distant from the NNRTI binding pocket decrease inhibitor binding (increas
259  of efavirenz binding extend > 60 A from the NNRTI binding pocket.
260 cooperative unfolding of a beta-sheet in the NNRTI binding pocket, which was previously observed in u
261 in the lopinavir-ritonavir group than in the NNRTI group (5.6% vs. 2.3%, P=0.16).
262  levels significantly more frequently in the NNRTI group.
263 in the lopinavir-ritonavir group than in the NNRTI group.
264 iviral activity against HIV-1, including the NNRTI-resistant Y188L mutated virus.
265                       The interaction of the NNRTI nevirapine (NVP) with HIV-1 reverse transcriptase
266 (R))) and an extended release version of the NNRTI nevirapine, (Viramune XR((R))) were recent additio
267 based regimen than among those receiving the NNRTI-based regimen (1.32 vs. 2.25 episodes per person-y
268 nvolvement of binding site(s) other than the NNRTI binding pocket.
269                             We show that the NNRTI binding pocket (NNIBP) is proximal to the hinge po
270 th WT RT suggested an optimal binding to the NNRTI binding pocket favoring the high anti-viral potenc
271 regions of RT heterodimer in addition to the NNRTI binding site.
272 ly 600 ns), we have captured RT bound to the NNRTI efavirenz in a closed conformation similar to that
273 e biochemical mechanism of resistance to the NNRTI nevirapine (NVP).
274                Other mutations linked to the NNRTI-resistant C181 lineage also resulted in altered NN
275 in addition to several interactions with the NNRTI binding pocket.
276 everse transcriptase (RT) genotypes with the NNRTI resistance mutations K101E+G190S are highly resist
277 articipants who initiated treatment with the NNRTI strategy, the risk of VF was significantly greater
278                                          The NNRTIs bind in an allosteric pocket in RT approximately
279 nucleoside RT inhibitors (NNRTI); therefore, NNRTI sensitivity was used to probe enzyme differences i
280  higher prevalence of HIV drug resistance to NNRTI in ART initiators.
281 nt HIV, potentially compromising response to NNRTI-based antiretroviral therapy (ART).
282 structures of RT(172R) and RT(172K) bound to NNRTIs or DNA/dNTP.
283 revalence of pretreatment drug resistance to NNRTIs is high.
284 ich CN and RH mutations confer resistance to NNRTIs, we hypothesized that these mutations reduce RNas
285 sociated with minority variants resistant to NNRTIs (HR, 2.6 [95% CI, 1.9-3.5]; P < .001).
286 TDR to NRTIs and PIs was <5%, whereas TDR to NNRTIs was 5%-15%.
287 e inhibitors of HIV-1 reverse transcriptase (NNRTIs).
288 orable resistance implications of PI- versus NNRTI-based first line therapy, widespread use of PI-bas
289 st likely occurs through a mechanism whereby NNRTIs stimulate priming or elongation of the tRNA.
290  rates <400 copies/ml were 8/13 (61.5%) with NNRTI-RAMs, 7/11 (63.6%) with NRTI-RAMs only, and 51/59
291        Since a major problem associated with NNRTI treatment is the emergence of drug resistant virus
292 ndomized clinical trials comparing bPI- with NNRTI-based first-line antiretroviral therapy regimens u
293 pinavir-ritonavir-based ART as compared with NNRTI-based ART reduced the incidence of malaria by 41%,
294              Combining the D549N mutant with NNRTI BP mutants further increases NNRTI resistance from
295 /=1 NNRTI-RAM, including eight patients with NNRTI-RAMs detected only by sensitive testing.
296 d 0.17 (95% CI 0.03, 1.15) for patients with NNRTI-RAMs or NRTI-RAMs only respectively vs. those with
297 d correlate the detection of resistance with NNRTI concentrations after treatment interruption and vi
298 215F/Y) were found to be highly stable, with NNRTI and PI mutations being relatively less persistent.
299 of virological failure during treatment with NNRTI-containing regimens.
300 olymerase chain reaction in subjects without NNRTI resistance by population sequencing.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top